Early Provenge

PROCEED Registry Show Men with Low PSA Scores Have a Median Survival Longer Then Four Years

Results from the PROCEED registry found that men with advanced prostate cancer with low PSA had a median survival of nearly 4 years after treatment with PROVENGE® (sipuleucel-T). A median survival means that one half of the men who participated in the registry lived longer than four years.

Provenge When Used In Castrate Sensitive Men with Prostate Cancer Changes PSA Kinetics, But Does Not Effect Time To Bio-Chemical Failure 

The understanding that the earlier Provenge is used in castrate resistant men with prostate cancer has led many men to ask why not use Provenge even earlier when they are still castrate sensitive?  This question is an excellent one which follows the logical next step; however, the answer is surprising!